[1]刘潺潺,李婷.重症肌无力-生活质量-15项评分在中国重症肌无力患者中的应用分析[J].卒中与神经疾病杂志,2017,24(05):458-460.[doi:10.3969/j.issn.1007-0478.2017.05.020]
点击复制

重症肌无力-生活质量-15项评分在中国重症肌无力患者中的应用分析()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第24卷
期数:
2017年05期
页码:
458-460
栏目:
论 著
出版日期:
2017-10-26

文章信息/Info

文章编号:
1007-0478(2017)05-0458-03
作者:
刘潺潺; 李婷
518000 深圳光明新区人民医院神经内科(刘潺潺); 心内科[李婷(通信作者)]
关键词:
重症肌无力 重症肌无力-生活质量-15项评分 生活质量
分类号:
R746.1
DOI:
10.3969/j.issn.1007-0478.2017.05.020
摘要:
目的 探讨重症肌无力-生活质量-15项评分(MG-QoL-15)在我国重症肌无力患者中的应用。方法 收集2014年4月～2016年3月确诊MG患者,病情处于稳定期,记录包括年龄、性别、当前MGFA级、最差的MGFA及治疗方案,治疗性干预包括胸腺切除术、胆碱酯酶抑制剂、激素和其它免疫抑制剂; 用MG-QOL-15中文版来评分,每个项目评分上标准是“0分”,“1分”,“2分”,“3分”和“4分”代表“完全没有”、“偶有”、“有一些”、“经常有”和“非常多”。结果 共纳入65例患者,MGFA Ⅰ患者是13例,MGFA Ⅱ是17例,MGFA Ⅲ是14例,MGFA Ⅳ是21例,平均MG-QOL-15评分(7.22±6.44)分,当前等级MGFA和口服强的松与生活质量分数有关; 性别、年龄>40岁、胸腺切除、口服溴吡斯的明的例数无显著差异(P>0.05)。结论 MG-QOL-15评分是一种简单、快捷、人性化的工具,有利于更好地评估治疗效果。

参考文献/References:

[1] Kumar R,Nagappa M,Sinha S,et al.MG-QoL-15 scores in treated myasthenia gravis: Experience from a university hospital in India[J].Neurol India,2016,64(3):405-410.
[2] Mourão AM,Gomez RS,Barbosa LS,et al.Determinants of quality of Life in Brazilian patients with myasthenia gravis[J].Clinics(Sao Paulo),2016,71(7):370-374.
[3] Leonardi M,Raggi A,Antozzi C,et al.The relationship between health,disability and quality of Life in myasthenia gravis: results from an Italian study[J].J Neurol,2010,257(1):98-102.
[4] Burns TM,Graham CD,Rose MR,et al.Quality of Life and measures of quality of Life in patients with neuromuscular disorders[J].Muscle Nerve,2012,46(1):9-25.
[5] Masuda M,Utsugisawa K,Suzuki S,et al.The MG-QOL15 Japanese version: validation and associations with clinical factors[J].Muscle Nerve,2012,46(2):166-173.
[6] Padua L,Evoli A,Aprile I,et al.Health-related quality of Life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements[J].Neurol Sci,2001,22(5):363-369.
[7] Burns TM,Grouse CK,Wolfe GI,et al.The MG-QOL15 for following the health-related quality of Life of patients with myasthenia gravis[J].Muscle Nerve,2011,43(1):14-18.
[8] Burns TM,Conaway M,Sanders DB,et al.The MG composite: a valid and reliable outcome measure for myasthenia gravis[J].Neurology,2010,74(18):1434-1440.
[9] Utsugisawa K,Suzuki S,Nagane Y,et al.Health-related quality-of-life and treatment targets in myasthenia gravis[J].Muscle Nerve,2014,50(4):493-500.
[10] Barnett C,Wilson G,Barth D,et al.Changes in quality of Life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis[J].J Neurol Neurosurg Psychiatry,2013,84(1):94-97.

更新日期/Last Update: 2017-10-20